

Stacy W Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/932199/publications.pdf>

Version: 2024-02-01

95
papers

4,355
citations

117625

34
h-index

114465

63
g-index

99
all docs

99
docs citations

99
times ranked

7622
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	1.6	96
2	A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research. <i>JAMA Health Forum</i> , 2022, 3, e220603.	2.2	13
3	Oncologists'™ perceptions of the usefulness of cancer survivorship care plan components. <i>Supportive Care in Cancer</i> , 2021, 29, 945-954.	2.2	4
4	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , 2021, 17, e1821-e1829.	2.9	4
5	Germline mutations and age at onset of lung adenocarcinoma. <i>Cancer</i> , 2021, 127, 2801-2806.	4.1	14
6	Personalized Cancer Medicine in the Media: Sensationalism or Realistic Reporting?. <i>Journal of Personalized Medicine</i> , 2021, 11, 741.	2.5	5
7	Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. <i>JCO Oncology Practice</i> , 2021, 17, e999-e1011.	2.9	3
8	Recall of Genomic Testing Results Among Patients with Cancer. <i>Oncologist</i> , 2021, 26, e2302-e2305.	3.7	8
9	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. <i>Clinical Lung Cancer</i> , 2021, 22, e703-e707.	2.6	5
10	A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	6
11	Association of Physician Peer Influence With Subsequent Physician Adoption and Use of Bevacizumab. <i>JAMA Network Open</i> , 2020, 3, e1918586.	5.9	22
12	Circulating tumor DNA as an early cancer detection tool. , 2020, 207, 107458.		123
13	Factors influencing cancer genetic somatic mutation test ordering by cancer physician. <i>Journal of Translational Medicine</i> , 2020, 18, 431.	4.4	11
14	Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice. <i>JCO Precision Oncology</i> , 2020, 4, 620-631.	3.0	22
15	Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. <i>JCO Precision Oncology</i> , 2020, 4, 307-318.	3.0	10
16	Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 866-872.	4.9	14
17	Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies. <i>Genetics in Medicine</i> , 2019, 21, 2781-2790.	2.4	55
18	Influence of Peer Physicians on Intensity of End-of-Life Care for Cancer Decedents. <i>Medical Care</i> , 2019, 57, 468-474.	2.4	6

#	ARTICLE	IF	CITATIONS
19	The effects of genomic germline variant reclassification on clinical cancer care. <i>Oncotarget</i> , 2019, 10, 417-423.	1.8	40
20	Hypertension and use of bevacizumab among patients treated in community settings.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18279-e18279.	1.6	0
21	Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1518-1518.	1.6	0
22	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6531-6531.	1.6	1
23	Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1059-1066.	6.3	48
24	Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. <i>Cancer</i> , 2018, 124, 2205-2211.	4.1	6
25	Interactive or static reports to guide clinical interpretation of cancer genomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 458-464.	4.4	14
26	Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	3.0	63
27	What Does a Cancer Diagnosis Mean? Public Expectations in a Shifting Therapeutic Environment. <i>Journal of Oncology Practice</i> , 2018, 14, 139-140.	2.5	1
28	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 3459-3465.	1.6	79
29	Factors contributing to disparities in mortality among patients with nonâ€“smallâ€“cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 5832-5842.	2.8	9
30	Use of next-generation sequencing tests to guide cancer treatment: Results from a survey of U.S. oncologists.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6529-6529.	1.6	0
31	Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer. , 2018, , .		0
32	Differences in comprehension of somatic genomic profiling between younger and older adults with advanced genitourinary cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 228-228.	1.6	0
33	Oncologistsâ€™ perspectives on post-cancer treatment communication and care coordination with primary care physicians. <i>European Journal of Cancer Care</i> , 2017, 26, e12628.	1.5	20
34	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. <i>Genetics in Medicine</i> , 2017, 19, 787-795.	2.4	46
35	Consumer Perspectives on Access to Directâ€“toâ€“Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience. <i>Milbank Quarterly</i> , 2017, 95, 291-318.	4.4	22
36	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. <i>Personalized Medicine</i> , 2017, 14, 37-50.	1.5	15

#	ARTICLE	IF	CITATIONS
37	Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study. Journal of Clinical Oncology, 2017, 35, 636-644.	1.6	34
38	Medical Oncologistsâ€™ Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. Journal of Oncology Practice, 2017, 13, e185-e196.	2.5	17
39	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.. Journal of Clinical Oncology, 2017, 35, 1514-1514.	1.6	3
40	What does the general population think about chemotherapy shortages?. Journal of Clinical Oncology, 2017, 35, 6530-6530.	1.6	0
41	Optimizing somatic genomic reporting and physician interpretation with web-based, interactive technologies.. Journal of Clinical Oncology, 2017, 35, 1517-1517.	1.6	0
42	Abstract 4273: Variant reclassifications in hereditary cancer genetics and their implications for clinical care. , 2017, , .		0
43	Quality in the Age of Precision Medicine: The Clinician Perspective. Journal of Oncology Practice, 2016, 12, 839-843.	2.5	8
44	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	6.2	137
45	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine, 2016, 8, 79.	8.2	151
46	Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Annals of Surgical Oncology, 2016, 23, 990-997.	1.5	17
47	Tip of the Tongue. New England Journal of Medicine, 2016, 375, 880-886.	27.0	3
48	ReCAP: Oncologistsâ€™ Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. Journal of Oncology Practice, 2016, 12, 259-260.	2.5	3
49	Oncologistsâ€™ and cancer patientsâ€™ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine, 2016, 18, 1011-1019.	2.4	108
50	Antiâ€“PD-1 Inhibitorâ€“Related Pneumonitis in Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2016, 4, 289-293.	3.4	135
51	Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories: Table 1.. Journal of the National Cancer Institute, 2016, 108, djv351.	6.3	86
52	Deliberations of a precision medicine tumor board.. Journal of Clinical Oncology, 2016, 34, e13005-e13005.	1.6	1
53	Pediatric oncology provider views on biopsying solid tumors in children with relapsed or refractory disease for the purpose of genomic profiling.. Journal of Clinical Oncology, 2016, 34, 10566-10566.	1.6	0
54	Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities.. Journal of Clinical Oncology, 2016, 34, 1500-1500.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine.. Journal of Clinical Oncology, 2016, 34, 11565-11565.	1.6	0
56	Accessibility and Quality of Online Cancer-Related Clinical Trial Information for Naïve Searchers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1629-1631.	2.5	15
57	Marketing of Personalized Cancer Care on the Web: An Analysis of Internet Websites. Journal of the National Cancer Institute, 2015, 107, .	6.3	16
58	Oncologists' Experiences With Drug Shortages. Journal of Oncology Practice, 2015, 11, e154-e162.	2.5	27
59	Tumor Board Participation Among Physicians Caring for Patients With Lung or Colorectal Cancer. Journal of Oncology Practice, 2015, 11, e267-e278.	2.5	54
60	CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 1231-1242.	4.4	73
61	Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. Genetics in Medicine, 2014, 16, 727-735.	2.4	60
62	Associations between Cancer-Related Information Seeking and Receiving PET Imaging for Routine Cancer Surveillance—An Analysis of Longitudinal Survey Data. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 481-489.	2.5	9
63	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	6.2	342
64	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine, 2014, 20, 682-688.	30.7	508
65	Physicians' Attitudes About Multiplex Tumor Genomic Testing. Journal of Clinical Oncology, 2014, 32, 1317-1323.	1.6	203
66	Cancer patients'™ preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study.. Journal of Clinical Oncology, 2014, 32, 1535-1535.	1.6	1
67	A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genetics in Medicine, 2013, 15, 824-832.	2.4	62
68	Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine, 2013, 15, 860-867.	2.4	99
69	An Analysis of the Association Between Cancer-Related Information Seeking and Adherence to Breast Cancer Surveillance Procedures. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 167-174.	2.5	12
70	Class, race and ethnicity and information avoidance among cancer survivors. British Journal of Cancer, 2013, 108, 1949-1956.	6.4	43
71	Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas. Journal of Thoracic Oncology, 2013, 8, 322-328.	1.1	145
72	Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
73	Update on Direct-to-Consumer Marketing in Oncology. <i>Journal of Oncology Practice</i> , 2012, 8, 124-127.	2.5	13
74	Patientâ€“Clinician Information Engagement Improves Adherence to Colorectal Cancer Surveillance after Curative Treatment: Results from a Longitudinal Study. <i>Oncologist</i> , 2012, 17, 1155-1162.	3.7	23
75	Attitudes of Patients With Cancer About Personalized Medicine and Somatic Genetic Testing. <i>Journal of Oncology Practice</i> , 2012, 8, 329-335.	2.5	104
76	Seeking Cancer-Related Information From Media and Family/Friends Increases Fruit and Vegetable Consumption Among Cancer Patients. <i>Health Communication</i> , 2012, 27, 380-388.	3.1	63
77	Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Nonâ€“Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1593.	7.4	110
78	The impact of risk information exposure on women's beliefs about directâ€“toâ€“consumer genetic testing for <i>BRCA</i> mutations. <i>Clinical Genetics</i> , 2012, 81, 29-37.	2.0	14
79	Looking Beyond the Internet: Examining Socioeconomic Inequalities in Cancer Information Seeking Among Cancer Patients. <i>Health Communication</i> , 2012, 27, 806-817.	3.1	51
80	Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 1404-1411.	4.1	33
81	Direct-to-consumer genetic testing and its potential impact on patient care: what oncologists need to know. <i>Community Oncology</i> , 2011, 8, 419-422.	0.2	0
82	Class, race, ethnicity and information needs in post-treatment cancer patients. <i>Patient Education and Counseling</i> , 2011, 85, 432-439.	2.2	45
83	How does patientâ€“clinician information engagement influence selfâ€“reported cancerâ€“related problems?. <i>Cancer</i> , 2011, 117, 2569-2576.	4.1	14
84	Variations in Surgeon Treatment Recommendations for Lobectomy in Early-Stage Non-Small-Cell Lung Cancer by Patient Age and Comorbidity. <i>Annals of Surgical Oncology</i> , 2010, 17, 1581-1588.	1.5	14
85	Differences in information seeking among breast, prostate, and colorectal cancer patients: Results from a population-based survey. <i>Patient Education and Counseling</i> , 2010, 81, S54-S62.	2.2	155
86	How Do Cancer Patients Navigate the Public Information Environment? Understanding Patterns and Motivations for Movement Among Information Sources. <i>Journal of Cancer Education</i> , 2010, 25, 360-370.	1.3	39
87	Internet use leads cancer patients to be active health care consumers. <i>Patient Education and Counseling</i> , 2010, 81, S63-S69.	2.2	105
88	Cancer Information Scanning and Seeking in the General Population. <i>Journal of Health Communication</i> , 2010, 15, 734-753.	2.4	168
89	Examining Cross-Source Engagement With Cancer-Related Information and Its Impact on Doctorâ€“Patient Relations. <i>Health Communication</i> , 2009, 24, 723-734.	3.1	43
90	Risk Information Exposure and Direct-to-Consumer Genetic Testing for <i>BRCA</i> Mutations among Women with a Personal or Family History of Breast or Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1303-1311.	2.5	31

#	ARTICLE	IF	CITATIONS
91	Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications. <i>Cancer</i> , 2009, 115, 1424-1434.	4.1	23
92	Attitudes Toward Research Participation and Investigator Conflicts of Interest Among Advanced Cancer Patients Participating in Early Phase Clinical Trials. <i>Journal of Clinical Oncology</i> , 2007, 25, 3488-3494.	1.6	29
93	Direct-to-Consumer Marketing of Genetic Tests for Cancer: Buyer Beware. <i>Journal of Clinical Oncology</i> , 2003, 21, 3191-3193.	1.6	48
94	Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. <i>Breast Cancer Research and Treatment</i> , 1998, 52, 147-158.	2.5	45
95	Cross-sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment. <i>Journal of Genetic Counseling</i> , 0, , .	1.6	0